Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Eupraxia Pharmaceuticals Inc. (T.EPR) had Stock-Based Compensation of 3.09M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
-18.19M |
|
-- |
|
-- |
|
-- |
|
-21.89M |
|
-- |
|
-17.34M |
|
-17.34M |
|
-17.36M |
|
-17.36M |
|
-17.36M |
|
-17.36M |
|
-21.89M |
|
-21.77M |
|
56.71M |
|
56.71M |
|
-0.32 |
|
-0.32 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
199.44M |
|
-- |
|
-- |
|
-- |
|
12.58M |
|
146.06M |
|
186.86M |
|
186.86M |
|
61.81M |
|
| Cash Flow Statement Financials | |
-13.92M |
|
-109.84M |
|
94.10M |
|
110.54M |
|
80.27M |
|
-30.27M |
|
|
Stock-Based Compensation |
3.09M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.30 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.37M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.89% |
|
-9.29% |
|
-8.71% |
|
-9.17% |
|
3.02 |
|
-0.25 |
|
-0.25 |
|